miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer

Lin,Lin; Lin,Haibo; Wang,Lin; Wang,Bin; Hao,Xuezhi; Shi,Yuankai

doi:10.3892/or.2015.4301

miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer

Authors:
- Lin Lin
- Haibo Lin
- Lin Wang
- Bin Wang
- Xuezhi Hao
- Yuankai Shi
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100021, P.R. China, Department of Thoracic Surgery, Peking University, First Hospital, Beijing 100034, P.R. China
Published online on: September 22, 2015 https://doi.org/10.3892/or.2015.4301
Pages: 3088-3096

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common cancer as well as the leading cause of cancer-related mortalities worldwide. Macrophages are the most abundant immune cells in primary and metastatic tumors, and contribute to tumor initiation, progression and metastasis. Macrophages have been shown to demonstrate a high level of plasticity, with the ability to undergo dynamic transition between M1 and M2 polarized phenotypes. In the present study, we investigated a pivotal role of miR-130a in macrophage polarization and whether it was associated with poor prognosis in non-small cell lung cancer (NSCLC), using RT-qPCR and western blot analyses. The in vitro experiments showed that miRNA-130a was expressed at a higher level in M1 compared to M2 macrophages. The enforced expression of miR-130a in macrophages resulted in a significantly increased production of proinflammatory cytokines, whereas deletion of miR-130a impaired the M2‑associated gene expression and led to an M1-biased response. Mechanistically, the bioinformatics analysis revealed that proliferator-activated receptor γ (PPARγ) is a potential target of miR-130a. Additionally, the luciferase assay confirmed that PPARγ translation was suppressed by miR-130a through the interaction with the 3'UTR of PPARγ mRNA. A subsequent analysis revaled that the induction of miR-130a suppressed PPARγ protein expression. In NSCLC patients, the results showed that miR-130a downregulation exhibited clinical relevance as it was correlated with poor prognosis and increased tumor stage and metastasis. In addition, miR‑130a was inversely correlated with the macrophage marker, CD163, and target gene, PPARγ. Taken together, the results established miR-130a as a molecular switch during macrophage development and as a potential target for the treatment of NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Byers LA and Rudin CM: Small cell lung cancer: Where do we go from here? Cancer. 121:664–672. 2015. View Article : Google Scholar
3	Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al: Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cook J and Hagemann T: Tumour-associated macrophages and cancer. Curr Opin Pharmacol. 13:595–601. 2013. View Article : Google Scholar : PubMed/NCBI
5	Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 3:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
6	Ruffell B and Coussens LM: Macrophages and therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015. View Article : Google Scholar : PubMed/NCBI
7	Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M and Udalova IA: IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 12:231–238. 2011. View Article : Google Scholar : PubMed/NCBI
8	Allavena P, Sica A, Solinas G, Porta C and Mantovani A: The inflammatory microenvironment in tumor progression: The role of tumor-associated macrophages. Crit Rev Oncol Hematol. 66:1–9. 2008. View Article : Google Scholar
9	Sica A and Mantovani A: Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI
10	Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, et al: Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 62:1757–1768. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ruhrberg C and De Palma M: A double agent in cancer: Deciphering macrophage roles in human tumors. Nat Med. 16:861–862. 2010. View Article : Google Scholar : PubMed/NCBI
12	Chen P and Bonaldo P: Role of macrophage polarization in tumor angiogenesis and vessel normalization: Implications for new anticancer therapies. Int Rev Cell Mol Biol. 301:1–35. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ohri CM, Shikotra A, Green RH, Waller DA and Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 33:118–126. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zhang J, Cao J, Ma S, Dong R, Meng W, Ying M, Weng Q, Chen Z, Ma J, Fang Q, et al: Tumor hypoxia enhances non-small cell lung cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling. Oncotarget. 5:9664–9677. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sun J, Mao Y, Zhang YQ, Guo YD, Mu CY, Fu FQ and Zhang XG: Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer. Oncol Lett. 6:1253–1260. 2013.PubMed/NCBI
16	Domagala-Kulawik J: The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res. 4:177–190. 2015.PubMed/NCBI
17	Bartel DP: MicroRnAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
18	Hammond SM: An overview of microRnAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
19	Lan H, Lu H, Wang X and Jin H: MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
20	Jasinski-Bergner S, Mandelboim O and Seliger B: The role of microRNAs in the control of innate immune response in cancer. J Natl Cancer Inst. 106:dju2572014. View Article : Google Scholar : PubMed/NCBI
21	Park EK, Jung HS, Yang HI, Yoo MC, Kim C and Kim KS: Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 56:45–50. 2007. View Article : Google Scholar : PubMed/NCBI
22	Wang XF, Wang HS, Wang H, Zhang F, Wang KF, Guo Q, Zhang G, Cai SH and Du J: The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage polarization of THP-1 cells. Cell Immunol. 289:42–48. 2014. View Article : Google Scholar : PubMed/NCBI
23	Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, et al: Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70:5728–5739. 2010. View Article : Google Scholar : PubMed/NCBI
24	Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L and De Palma M: A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood. 114:901–914. 2009. View Article : Google Scholar : PubMed/NCBI
25	Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et al: HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 19:31–44. 2011. View Article : Google Scholar : PubMed/NCBI
26	Alam MM and O'Neill LA: MicroRNAs and the resolution phase of inflammation in macrophages. Eur J Immunol. 41:2482–2485. 2011. View Article : Google Scholar : PubMed/NCBI
27	He M, Xu Z, Ding T, Kuang DM and Zheng L: MicroRnA-155 regulates inflammatory cytokine production in tumor-associated macrophages via targeting C/EBPbeta. Cell Mol Immunol. 6:343–352. 2009. View Article : Google Scholar : PubMed/NCBI
28	Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:79–82. 1998. View Article : Google Scholar : PubMed/NCBI
29	Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, et al: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6:137–143. 2007. View Article : Google Scholar : PubMed/NCBI
30	Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D and Glass CK: Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature. 400:378–382. 1999. View Article : Google Scholar : PubMed/NCBI
31	Berry A, Balard P, Coste A, Olagnier D, Lagane C, Authier H, Benoit-Vical F, Lepert JC, Séguéla JP, Magnaval JF, et al: IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur J Immunol. 37:1642–1652. 2007. View Article : Google Scholar : PubMed/NCBI
32	Becker M, Müller CB, De Bastiani MA and Klamt F: The prognostic impact of tumor-associated macrophages and intratumoral apoptosis in non-small cell lung cancer. Histol Histopathol. 29:21–31. 2014.
33	Xue Z, Wen J, Chu X and Xue X: A microRNA gene signature for identification of lung cancer. Surg Oncol. 23:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
34	Wali RK, Hensing TA, Ray DW, Dela Cruz M, Tiwari AK, Radosevich A, Jepeal L, Fernando HC, Litle VR, Charlot M, et al: Buccal microRnA dysregulation in lung field carcinogenesis: gender-specific implications. Int J Oncol. 45:1209–1215. 2014.PubMed/NCBI
35	Piva R, Spandidos DA and Gambari R: From microRnA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol. 43:985–994. 2013.PubMed/NCBI
36	Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol. 8:384–393. 2015.PubMed/NCBI
37	Chen H, Li X, Li W and Zheng H: miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DnA methyltransferase. J Transl Med. 13:692015. View Article : Google Scholar : PubMed/NCBI
38	Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli G, et al: miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 31:634–642. 2012.
39	Maniecki MB, Etzerodt A, Ulhøi BP, Steiniche T, Borre M, Dyrskjøt L, Orntoft TF, Moestrup SK and Møller HJ: Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 131:2320–2331. 2012. View Article : Google Scholar : PubMed/NCBI
40	He KF, Zhang L, Huang CF, Ma SR, Wang YF, Wang WM, Zhao ZL, Liu B, Zhao YF, Zhang WF, et al: CD163 tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int. 2014:8386322014. View Article : Google Scholar
41	De Palma M and Lewis CE: Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell. 23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI